Infigratinib low dose therapy is an effective strategy to treat hypochondroplasia

Area of Science:

• Genetics
• Molecular Biology
• Pharmacology

Background:

• Hypochondroplasia is a rare genetic skeletal dysplasia caused by FGFR3 variants, leading to disproportionate short stature.
• No precision therapies are currently approved for hypochondroplasia.
• Infigratinib, an FGFR1-3 inhibitor, targets the underlying pathophysiology of FGFR3-related skeletal dysplasias.

Purpose of the Study:

• To evaluate the therapeutic relevance of infigratinib for hypochondroplasia.
• To assess infigratinib's efficacy through in silico, in vitro, and in vivo models.
• To support the clinical development of infigratinib for hypochondroplasia treatment.

Main Methods:

• In silico assessment of infigratinib interaction with hypochondroplasia-associated FGFR3 variants.
• In vitro studies to determine infigratinib's inhibitory effect on FGFR3.
• Evaluation of infigratinib in a mouse model of hypochondroplasia (Fgfr3N534K/+) for skeletal growth improvement.

Main Results:

• In silico analysis indicated strong interaction between infigratinib and relevant FGFR3 variants.
• In vitro experiments confirmed potent inhibitory activity of infigratinib.
• In the hypochondroplasia mouse model, infigratinib treatment led to significant improvements in skeletal growth.

Conclusions:

• Preclinical data strongly support infigratinib's therapeutic potential for hypochondroplasia.
• Infigratinib effectively targets the molecular mechanisms of hypochondroplasia.
• Findings, combined with Phase 2 achondroplasia data, warrant further development of infigratinib for hypochondroplasia.